Trichomoniasis and Atrophic Vaginitis are easy to mix up on the boards. Here's a side-by-side comparison — presentation, workup, imaging, and first-line treatment — drawn from our full outlines.
Atrophic Vaginitis: Hypoestrogenic atrophy of vulvovaginal and lower urinary tract tissues.
Try two board-style questions on Trichomoniasis vs Atrophic Vaginitis
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1ReproductiveMedium
A 26-year-old woman presents with 5 days of frothy, malodorous yellow-green vaginal discharge, vulvar itching, and burning with urination. She is not pregnant and has had two new partners in the past 2 months. On speculum exam there is vaginal erythema and punctate cervical hemorrhages. Vaginal pH is 5.5, and saline wet mount shows motile, pear-shaped flagellated organisms. Which of the following is the most appropriate initial management?
AMetronidazole 250 mg orally three times daily for 7 days
BMetronidazole 500 mg orally twice daily for 7 days
CMetronidazole 2 g orally as a single one-time dose
DMetronidazole 0.75% vaginal gel nightly for 5 days
Reveal answer & full explanation
Correct answer: B — Metronidazole 500 mg orally twice daily for 7 days
AMetronidazole 250 mg orally three times daily for 7 days
BMetronidazole 500 mg orally twice daily for 7 days✓
CMetronidazole 2 g orally as a single one-time dose
DMetronidazole 0.75% vaginal gel nightly for 5 days
Why Metronidazole 500 mg orally twice daily for 7 days is correct
The frothy yellow-green discharge, strawberry cervix (punctate hemorrhages), pH >4.5, and motile flagellated trichomonads on wet mount confirm Trichomonas vaginalis vaginitis.
Per CDC 2021 STI treatment guidelines, first-line therapy for women is metronidazole 500 mg PO BID for 7 days; this multidose regimen replaced the single 2 g dose in women because the 7-day course produces lower recurrence.
Sexual partners should also be treated, and the patient should be re-tested within 3 months given high reinfection rates.
Why the others are wrong
Metronidazole 2 g orally as a single one-time dose — correct drug class, but the single dose is now first-line only for men; in women it has higher recurrence and is no longer preferred.
Metronidazole 250 mg orally three times daily for 7 days — a superseded lower-dose oral regimen that delivers less total drug than the currently recommended course; CDC specifies 500 mg twice daily for 7 days in women.
Metronidazole 0.75% vaginal gel nightly for 5 days — topical metronidazole treats bacterial vaginosis but does not reach therapeutic levels in the urethra and periurethral glands where trichomonads persist, so cure rates are poor and it is explicitly not recommended for trichomoniasis.
Question 2ReproductiveMedium
A 52-year-old woman reports 6 months of progressive vaginal dryness, burning, and pain with intercourse, along with new urinary urgency. Three years ago she underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy for benign disease and has taken no hormone therapy since. She has had three vaginal deliveries, smokes half a pack of cigarettes daily, and has been sexually active monthly with her partner. On exam the vaginal mucosa is pale, thin, and friable with loss of rugae, and the introitus is narrowed. Which of the following is the strongest risk factor for her condition?
AInfrequent vaginal intercourse
BHeavy long-term cigarette smoking
CEstrogen loss from oophorectomy
DMultiple prior vaginal deliveries
Reveal answer & full explanation
Correct answer: C — Estrogen loss from oophorectomy
AInfrequent vaginal intercourse
BHeavy long-term cigarette smoking
CEstrogen loss from oophorectomy✓
DMultiple prior vaginal deliveries
Why Estrogen loss from oophorectomy is correct
Atrophic vaginitis (genitourinary syndrome of menopause, GSM) is driven by estrogen deficiency, which thins the vaginal epithelium, raises vaginal pH above 5, depletes lactobacilli, and reduces lubrication and elasticity.
Bilateral oophorectomy abruptly removes the dominant source of endogenous estrogen, producing a profound and immediate hypoestrogenic state, the single strongest determinant of GSM and a far greater driver than the lifestyle factors listed.
The pale, thin, friable mucosa with loss of rugae and narrowed introitus in an estrogen-deprived patient is the classic picture; per NAMS/ISSWSH the condition is defined by the hypoestrogenic state itself.
Why the others are wrong
Heavy long-term cigarette smoking is a genuine but weaker contributor; it lowers estrogen levels and hastens menopause, modifying risk rather than serving as the primary cause.
Multiple prior vaginal deliveries relate to pelvic floor disorders and prolapse, not to the estrogen-deficient mucosal atrophy of GSM, and parity is not an established risk factor for the condition.
Infrequent vaginal intercourse can worsen atrophy through loss of vascular response, but it is a minor contributor and this patient remains regularly active, so it cannot outweigh surgical estrogen loss.
🔒 Free preview limit reached
Keep comparing — start your free trial
You've used your 2 free previews. Create your free account to see the full Trichomoniasis vs Atrophic Vaginitis comparison — plus all 514 diagnosis outlines, 7,200+ board-style questions, and an AI tutor. Your 7-day free trial includes everything, no credit card required.
Hypoestrogenic atrophy of vulvovaginal and lower urinary tract tissues.
Classic presentation
Sexually active woman with frothy malodorous discharge, vulvar pruritus, and strawberry cervix on colposcopy or speculum exam.; Frothy, malodorous yellow-green discharge; Vulvar and vaginal pruritus, burning; Dyspareunia, dysuria; Postcoital bleeding; ~50% of women and most men are asymptomatic; Frothy yellow-green discharge;…
Vulvovaginal: dryness, burning, irritation, dyspareunia, postcoital bleeding, loss of lubrication; Urinary: urgency, dysuria, recurrent UTI, urinary incontinence; Pale, thin, friable vaginal mucosa with loss of rugae; Decreased elasticity, vaginal shortening, narrow introitus; Petechiae or fissures with manipulation; cervical…
Workup / key labs
NAAT (nucleic acid amplification test) — preferred; high sensitivity/specificity; Wet mount microscopy — motile, pear-shaped flagellated trichomonads (~50-70% sensitivity); Point-of-care antigen tests (OSOM Trichomonas, Affirm VPIII) — better than wet mount, suitable for clinical setting; Culture (Diamond medium) — high specificity but…
Clinical — typical symptoms and exam findings in a hypoestrogenic patient, with exclusion of infection and dermatoses. Biopsy any suspicious lesion.; Wet mount: increased parabasal cells, paucity of lactobacilli, vaginal pH >5; Exclude infection: NAAT for GC/CT, wet mount or NAAT for trichomonas, KOH for yeast; Urinalysis if urinary…
Imaging
—
Not routinely needed
First-line treatment
Women: metronidazole 500 mg PO BID × 7 days (CDC 2021 — replaced single 2 g dose for women based on trial data showing lower recurrence with 7-day regimen); Men: metronidazole 2 g PO × 1 dose; Alternative: tinidazole 2 g PO × 1 dose
Non-hormonal: long-acting vaginal moisturizers (e.g., polycarbophil/Replens) 2-3x weekly, water- or silicone-based lubricants with intercourse; Continued sexual activity (with adequate lubrication) helps preserve vaginal tissue health
Drill Trichomoniasis vs Atrophic Vaginitis questions on FirstPassPA
Turn this comparison into retention. 7,200+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.